OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
October 08, 2021
Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.
Pfizer and BioNTech’s request would make them the first vaccine accessible to individuals under the age of 12.
October 07, 2021
The agency received a marketing authorization application a monoclonal antibody treatment for COVID-19 patients.
The agency’s human medicines committee approved an additional site in West Point, Pa. in the United States for the manufacture of Janssen’s COVID-19 vaccine.
October 06, 2021
The collaboration between Sunovion, Sumitomo Dainippon, and Otsuka will focus on four compounds designed to treat neuropsychiatric health conditions.
October 05, 2021
Merck and Ridgeback Biotherapeutics' oral antiviral medication reduced the risk of hospitalization or death from COVID-19 by 50% relative to placebo in a Phase III clinical study.
October 04, 2021
Takeda will use Selecta Bioscience’s ImmTOR platform to develop gene therapies for lysosomal storage disorders.
October 01, 2021
AstraZeneca’s acquisition of Caelum Biosciences gives them access to CAEL-101, a promising light chain amyloidosis treatment.
Pure Psyence, Pure Extracts and Psyence’s joint venture company, will develop psilocybin-derived treatments.
Merck’s 11.5 billion acquisition of Acceleron gives them access to their lead therapeutic candidate, sotatercept.